Fidelity Disruptive Medicine ETF (NASDAQ:FMED) Shares Purchased by Wealth Enhancement Advisory Services LLC

Wealth Enhancement Advisory Services LLC grew its stake in shares of Fidelity Disruptive Medicine ETF (NASDAQ:FMED) by 6.3% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 496,857 shares of the company’s stock after acquiring an additional 29,339 shares during the quarter. Wealth Enhancement Advisory Services LLC owned about 0.23% of Fidelity Disruptive Medicine ETF worth $12,680,000 at the end of the most recent quarter.

Fidelity Disruptive Medicine ETF Price Performance

NASDAQ FMED opened at $24.06 on Friday. Fidelity Disruptive Medicine ETF has a 12 month low of $19.88 and a 12 month high of $25.68. The company has a 50-day moving average of $24.03 and a 200-day moving average of $24.33. The company has a market cap of $51.01 million, a P/E ratio of 35.73 and a beta of 0.94.

Fidelity Disruptive Medicine ETF Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, June 25th. Investors of record on Friday, June 21st were given a dividend of $0.001 per share. This represents a $0.00 dividend on an annualized basis and a yield of 0.02%. The ex-dividend date of this dividend was Friday, June 21st.

Fidelity Disruptive Medicine ETF Profile

The Fidelity Disruptive Medicine ETF (FMED) is an exchange-traded fund that mostly invests in health care equity. The fund is an actively managed fund that invests in companies involved in disruptive innovation in Health Care. The fund invests in securities of domestic and foreign issuers FMED was launched on Apr 16, 2020 and is managed by Fidelity.